Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib + nivolumab + ipilimumab versus placebo + nivolumab + ipilimumab in previously untreated intermediate- or poor-risk advanced renal cell carcinoma
MOH_2019-08-19_007307Phase 3Completed
- Sponsor
- Exelixis, Inc.
- Start
- Aug 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cabozantinib, nivolumab and ipilimumab in renal cell carcinoma (RCC) (2 arms), sponsored by Exelixis, Inc. Started Aug 2019; status: completed.
02
Drugs
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on MOH_2019-08-19_007307.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-08-19_007307.